NOCIL Q1 FY27 Revenue Jumps 20% YoY to ₹403 Crore; EBITDA Up 48%
NOCIL Limited reported a 20% YoY revenue growth to ₹403 crore for Q1 FY27, driven by 9% volume growth and higher selling prices. EBITDA surged 48% YoY to ₹45 crore, with margins at 11.2%. PAT increased 61% YoY to ₹28 crore. The company expects FY27 revenue between ₹1,400-₹1,600 crore.
Significant financial performance improvement and positive outlook on future revenue and strategic investments are likely to have a high impact on investor sentiment.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary on future outlook and strategic initiatives like the new TDQ plant.
NOCIL Limited announced its financial results for the first quarter of FY27, reporting a significant 20% year-on-year increase in revenue from operations, reaching ₹403 crore. This growth was primarily driven by a healthy 9% volume increase and higher selling prices due to rising raw material costs. Domestic volumes saw double-digit growth, boosted by improved demand post-GST 2.0, while export volumes grew in single digits, supported by customer engagements and international market traction.
On a sequential basis, revenue grew by 22%, though volumes saw a slight 3% decline due to temporary supply-side constraints and logistical challenges. The company also noted a temporary demand contraction in the non-tyre segment due to input cost increases and labor shortages. NOCIL is working to recover deferred volumes in the coming quarters.
The company provided an update on anti-dumping petitions, with the government approving duties on Sulphonamides (CBS and NS) on June 20, 2026. A positive final recommendation was also received for Pilflex 13, awaiting government approval. Trial production at the new TDQ plant in Dahej is progressing well, with customer samples initiated, and the ₹130 crore investment is on track.
NOCIL expects FY27 revenue to be in the range of ₹1,400 to ₹1,600 crore, with EBITDA around 10%. For Q1 FY27, EBITDA stood at ₹45 crore, a 48% YoY increase, with EBITDA margins at 11.2%. Profit Before Tax (PBT) grew 60% YoY to ₹37 crore, and Profit After Tax (PAT) rose 61% YoY to ₹28 crore.
The company anticipates revenues from the TDQ plant to start trickling in from Q4 FY27, with more substantial contributions in Q1 FY28. The export mix was 33% and domestic was 67% in Q1. Management expressed optimism about the business progression despite global uncertainties, focusing on strategy execution, operational excellence, and prudent financial management.
What to do with a filing like this
NOCIL Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by NOCIL Limited. Read the original for the full detail.